White analytical insight for sensitive fluorescent determination of semaglutide and tirzepatide in pharmaceuticals and biological matrices.
Spectrochim Acta A Mol Biomol Spectrosc · 2024
Last updated 2026-05-28Researchers developed a method to detect two GLP-1 drugs, semaglutide and tirzepatide, in medications and human blood samples using fluorescence. The technique can measure very small amounts of the drugs—down to 10 nanograms per milliliter—and was tested in ethanol with specific light wavelengths. The method was found to be accurate when compared to other established techniques, and it was also evaluated for environmental friendliness.
AI summary of the abstract below.
| Journal | Spectrochim Acta A Mol Biomol Spectrosc, 2024 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.73 |
| NIH percentile | 40 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
The present study is focused on the sensitive determination of newly FDA-approved glucagon-like-peptide agonists semaglutide (SEM) and tirzepatide (TIR). Direct, selective and label-free spectrofluorometric method was proposed and validated (according to ICH guidelines) for determination SEM and TIR in their pure form, newly approved pharmaceuticals and spiked human plasma. The developed method was based on measuring the native fluorescence of SEM and TIR in ethanol at 294.8 and 303 nm after being excited at 216 and 225 nm for SEM and TIR in order. The method sensibility allowed the quantification of both drugs in nano-scale up to 10 ng/mL. Several experimental variables including solvent type, surfactant, and pH were optimized after several attempts to get the best sensitivity for both drugs. The mean recovery percentage of SEM was compared and found in agreement with the reported method using student's t-test and the variance ratio F-test. Additionally, the greenness and whiteness profiles for this approach were evaluated using the GAPI, AGREE, and RGB algorithm; the positive results supported its use as great candidates for successful implementation in quality control labs and the pharmaceutical analysis companies.
Verbatim abstract via PubMed 38508074 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.